Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart dise... The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

Lilly SURPASS-CVOT study result 🫀
Mounjaro not inferior to Trulicity

Primary endpoint:
Risk of cardiovascular death, heart attack, or stroke 8% lower for Mounjaro than Trulicity, but p = 0.086 📊

investor.lilly.com/news-release...

#Tirzepatide #Dulaglutide #Mounjaro #Trulicity #$LLY #NCT04255433